Jason Ryan - Foundation Medicine Insider

FMI -- USA Stock  

null 137.00  0.00  0.00%

Mr. Jason Ryan serves as a Chief Financial Officer, Principal Financial Officer, Principal Accounting officer of the Company. Mr. Ryan has served as our Chief Financial Officer since March 2015, as our Senior Vice President, Finance from January 2014 to March 2015 and as our Vice President, Finance from March 2012 to January 2014. He previously served as our Senior Director, Finance from May 2011 to March 2012. Prior to joining us, Mr. Ryan led the finance and strategic planning functions of Taligen Therapeutics, Inc., which was acquired by Alexion Pharmaceuticals, Inc., from May 2009 to April 2011, Codon Devices Inc. from May 2007 to May 2009 and Genomics Collaborative, Inc., which was acquired by SeraCare Life Sciences, Inc., from September 1998 to September 2004. He began his career at Deloitte Touche
Age: 42  CFO Since 2015  CPA    
617-418-2200  http://www.foundationmedicine.com
Ryan holds a B.S. in economics from Bates College and an M.B.A. from Babson College, and earned a C.P.A. in Massachusetts.

Jason Ryan Latest Insider Activity

Management Efficiency

The company has Return on Asset of (54.48) % which means that on every $100 spent on asset it lost $54.48. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (209.94) % meaning that it generated no profit with money invested by stockholders.
The company has 90 M in debt with debt to equity (D/E) ratio of 476.2 . This implies that the company may be unable to create cash to meet all of its financial commitments. Foundation Medicine has Current Ratio of 2.22 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Found 3 records

CFO Since

Richard DoyleFive Star Senior Living
Nigel RoseGAIN Capital Holdings
Douglas NeisThe Marcus Corporation

Entity Summary

Foundation Medicine, Inc. provides various molecular information products in the United States. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc. Foundation Medicine operates under Diagnostics Research classification in USA and traded on NASDAQ. It employs 662 people.Foundation Medicine (FMI) is traded on NASDAQ in USA. It is located in 150 Second Street and employs 662 people.

Foundation Medicine Leadership Team

Daniel Day, Director
Michael Varney, Director
Krishna Yeshwant, Independent Director
David Daly, Chief Commercial Officer
David Schenkein, Independent Director
Melanie Nallicheri, Chief business Officer and head of Biopharma
Alexis Borisy, Chairman of the Board, Co-Founder
Steven Kafka, Pres and COO
Evan Jones, Independent Director
Vincent Miller, Chief Medical Officer
Konstantin Fiedler, COO
Michael Pellini, President CEO, Director
Robert Hesslein, Senior Vice President General Counsel
Sandra Horning, Director
Michael Doherty, Head of Product Development
Jason Ryan, CFO
Michael Dougherty, Director
Tom Civik, Chief Commercial Officer
Troy Cox, CEO, Director
Thomas Civik, Chief Commercial Officer

Stock Performance Indicators

Current Sentiment - FMI

Foundation Medicine Investor Sentiment

Greater number of Macroaxis users are currently bullish on Foundation Medicine. What is your opinion about investing in Foundation Medicine? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally see Investing Opportunities. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.
Search macroaxis.com